Status:

COMPLETED

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Lead Sponsor:

GlaxoSmithKline

Conditions:

Restless Legs Syndrome

Restless Legs Syndrome (RLS)

Eligibility:

All Genders

18-79 years

Phase:

PHASE3

Brief Summary

This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole ...

Eligibility Criteria

Inclusion

  • Diagnosis of RLS using IRLS Study Group (IRLSSG) diagnostic criteria.
  • Subjects currently being treated for RLS with a stable dose (for at least 2 weeks) of ropinirole IR given once daily.
  • Subjects with RLS symptoms during both the evening and night or night time only.
  • Subjects who have given written informed consent to participate.

Exclusion

  • Subjects who require treatment of daytime RLS symptoms.
  • Signs of secondary RLS, serum ferritin level less than 10 mcg/L.
  • Movement Disorders, Clinically significant or unstable medical conditions.
  • Abnormal labs, electrocardiogram (ECG) or physical findings.
  • Receiving prohibited medications.
  • Sleeping habits incompatible with study design.
  • Intolerance to ropinirole or other dopamine agonist.
  • Pregnant or lactating.
  • Women of child-bearing potential who are not practicing an acceptable method of birth control.

Key Trial Info

Start Date :

November 14 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 21 2006

Estimated Enrollment :

135 Patients enrolled

Trial Details

Trial ID

NCT00256854

Start Date

November 14 2005

End Date

September 21 2006

Last Update

March 15 2019

Active Locations (30)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (30 locations)

1

GSK Investigational Site

Laguna Hills, California, United States, 82653

2

GSK Investigational Site

Oxnard, California, United States, 93030

3

GSK Investigational Site

Pasadena, California, United States, 91106

4

GSK Investigational Site

Reseda, California, United States, 91355